Mobile stroke units (MSU) enable rapid identification and treatment of thrombolytic-eligible patients with acute ischemic stroke (AIS). Recent studies have highlighted the benefit of MSUs over ...
Assessment of long-term toxicities of imatinib in CML: Experience from a tertiary care cancer centre in south India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Abstract: Chronic kidney disease (CKD) is a critical global health issue that can lead to end-stage renal failure if not diagnosed and managed early. Early detection and continuous monitoring of CKD ...
Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...
Midterm primaries and the general election are quickly approaching. Early voting for the Democratic and Republican primaries begins on Feb. 17. The last day of early voting for the primary elections ...
Abstract: Leukemia, a prevalent childhood cancer affecting the blood and bone marrow, necessitates a proactive approach to risk mitigation through lifestyle adaptations. Despite previous ...
The president’s announcement came after the center has been rocked by cancellations and boycotts by performers, contributors and audience members. By Adam Nagourney and Julia Jacobs President Trump ...
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. President Trump says he will move to close ...
The Democratic Party took a small step toward setting its 2028 presidential primary calendar, telling a dozen state parties they can formally present bids to hold nominating contests at the beginning ...
Acute myeloid leukemia (AML) is a heterogeneous malignancy marked by uncontrolled proliferation of myeloid precursor cells in the bone marrow (BM) and peripheral blood, leading to cytopenias and ...
Adopting zanubrutinib for the treatment of chronic lymphocytic leukemia showed improved tolerability and persistence, enhancing patient safety and outcomes. Margaret ...
Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free survival. Median progression-free survival was 9.5 years from initial treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results